OKYO Pharma reports positive results from Phase 2 neuropathic corneal pain trial, potential for nerve restoration with urcosimod.

OKYO Pharma's Phase 2 trial for neuropathic corneal pain (NCP) showed favorable outcomes with its investigational therapy urcosimod. Patients receiving 0.05% urcosimod showed increases in total nerve fiber count and length, while the placebo group showed decreases. The data suggest a potential positive effect of urcosimod on corneal nerve health in NCP patients, and the company believes it may open a new therapeutic avenue for patients with NCP. Shares of OKYO added 9.4% in Thursday morning trading.